T1	Participants 68 101	patients with Parkinson's disease
T2	Participants 242 289	two groups of patients with Parkinson's disease
T3	Participants 323 427	10 patients with a moderate motor impairment insufficiently controlled by monotherapy with bromocriptine
T4	Participants 462 517	eight patients with L-dopa-induced peak-dose dyskinesia
